SWOG A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD) Adult CIRB - Late Phase Emphasis Active Available to Open